IL-17A promotes ventricular remodeling after myocardial infarction

Area of Science:

• Cardiovascular Biology
• Immunology
• Molecular Medicine

Background:

• Inflammatory responses are critical in adverse ventricular remodeling post-myocardial infarction (MI).
• Interleukin-17A (IL-17A) has been implicated in myocardial ischemia/reperfusion injury and viral myocarditis.
• The specific role and mechanisms of IL-17A in post-MI remodeling remain incompletely understood.

Purpose of the Study:

• To investigate the role of IL-17A in the pathogenesis of ventricular remodeling after acute myocardial infarction (MI).
• To elucidate the underlying molecular mechanisms by which IL-17A influences cardiomyocyte apoptosis and cardiac function post-MI.

Main Methods:

• Acute myocardial infarction (MI) was induced in C57BL/6 mice via coronary artery ligation.
• The effects of IL-17A repletion and genetic IL-17A deficiency on cardiac structure and function were assessed.
• In vitro studies utilized neonatal cardiomyocytes to examine IL-17A-induced apoptosis signaling pathways.

Main Results:

• IL-17A repletion exacerbated ventricular remodeling, increasing infarct size, worsening cardiac function, and promoting fibrosis and cardiomyocyte apoptosis.
• Genetic deficiency of IL-17A demonstrated protective effects against adverse cardiac remodeling post-MI.
• In vitro, IL-17A induced cardiomyocyte apoptosis via activation of p38, p53 phosphorylation, and Bax redistribution.

Conclusions:

• IL-17A plays a significant pathogenic role in both early and late stages of post-MI ventricular remodeling.
• IL-17A induces cardiomyocyte apoptosis through the p38 MAPK-p53-Bax signaling pathway.
• Targeting IL-17A presents a potential therapeutic strategy for preventing heart failure following myocardial infarction.